ProShare Advisors
CAI

ProShare Advisors’s Caris Life Sciences CAI Stock Holding History

ProShare Advisors’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,622
Closed -$226K – 2044
2026
Q1 		$226K Buy
12,622
+160
+1% +$3.5K ﹤0.01% 1503
2025
Q4 		$336K Buy
+12,462
New +$351K ﹤0.01% 1381

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ProShare Advisors's CAI Position: Q2 2026 in Review

ProShare Advisors sold out of Caris Life Sciences (CAI) in Q2 2026, closing a stake of 12,622 shares — an estimated $226K sold.

ProShare Advisors first reported a position in CAI in Q4 2025 and held it in 2 quarters. The position peaked at $336K in Q4 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • ProShare Advisors reported no remaining Caris Life Sciences position as of Q2 2026 after selling out during the quarter.
  • ProShare Advisors sold 12,622 Caris Life Sciences shares in Q2 2026, an estimated $226K.
  • ProShare Advisors first reported a position in Caris Life Sciences in Q4 2025 and held it in 2 quarters.
  • ProShare Advisors's Caris Life Sciences position peaked at $336K in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.